Certified by Founder
Lodge
KROMATID®
start up
United States
- Longmont, Colorado
- 21/08/2025
- Series C
- $8,000,000
Revolutionizing gene editing analysis for precision medicine and cutting-edge research.
For cell and gene therapy researchers, biotech and pharma companies, and regulatory professionals, KROMATID’s KROMASURE Platform is the genomic characterization solution that provides high-confidence, single-cell insights into chromosomal integrity, structural variants, and transgene mapping.
Unlike traditional sequencing methods, our technology directly visualizes up to thousands of single cells at a time, offering scalable, actionable data with unprecedented clarity, helping you confidently advance research and meet FDA regulatory requirements.
Visit our website to learn how we can support your research.
- Industry Biotechnology Research
- Website https://kromatid.com/
- LinkedIn https://www.linkedin.com/company/kromatid/
DeepInfra | $107,000,000 | (May 5, 2026)
Kibu, Inc | $10,500,000 | (May 5, 2026)
Fun | $72,000,000 | (May 5, 2026)
Panthalassa | $140,000,000 | (May 5, 2026)
Featherless AI | $20,000,000 | (May 5, 2026)
Healthfab | $2,100,000 | (May 5, 2026)
LakeFusion | $7,500,000 | (May 5, 2026)
Enzo Health | $20,000,000 | (May 5, 2026)
Barocal | $10,000,000 | (May 5, 2026)
Zapdos Labs | $500,000 | (May 5, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)